CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

John Cox

Chief Executive Officer, Dyne Therapeutics

Search every verified John Cox interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. John Cox, CEO of Dyne Therapeutics, discussed the company's progress and strategy in several mid-2026 appearances. He described Dyne as being in a "transformational" growth phase as it prepares for its first product launches, with a focus on building commercial and medical capabilities. Cox highlighted the company's proprietary delivery technology, which uses a Fab fragment targeting the transferrin receptor to deliver oligonucleotides to muscle and the central nervous system, a method he said addresses limitations of prior approaches. He reported that clinical data in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) showed functional improvement from baseline, which he called "unprecedented" across all functional measures in a trial, and noted the company had submitted its first Biologics License Application (BLA). In separate panel discussions, Cox spoke about organizational leadership and capital allocation. He argued that decision-making is improved by clarity and speed rather than excessive structure, and emphasized that supply chain reliability is a critical area where failure is not an option. He also discussed the challenge of scaling manufacturing to serve small patient populations with rare genetic mutations, stating that the field must find economical ways to produce therapies for "the n of few" as well as larger groups.

Recent appearances

  • Dyne Therapeutics pioneers direct drug delivery to muscle and CNS

    July 15, 2026 · 📺 RBC Capital Markets

    Dyne Therapeutics is an early-stage company gearing up for its first launch, promising to tackle unmet need in patients with neuromuscular disease. President and CEO John Cox outlines the science behind the company’s ambitions, and the expansion efforts that will support its metamorphosis from early-stage company to fully-fledged biotech. Key Points • Dyne Therapeutics is pioneering a new delivery method for its products targeting neuromuscular disease. • With two launches planned, the business is preparing to transform from early-stage company to fully-integrated biotech. • Shared clini…

    Watch on YouTube ↗

  • Building organizations that keep pace with change

    June 11, 2026 · 📺 Danaher Corporation

    Scientific progress continues to accelerate, and expectations across the industry continue to rise. As timelines compress, organizations are increasingly defined by how they make decisions and execute consistently. This fireside chat focuses on the leadership and operating model choices required to translate ambition into results, how leaders clarify decisions, align incentives and establish accountability across teams with different pressures and time horizons. Moderated by Chris Riley, Cytiva Panelists: John Cox, Dyne Therapeutics Ann Lee, Prime Medicine Watch more videos from Danaher…

    Watch on YouTube ↗

  • The inflection point for nucleic acid drugs is a targeting problem

    June 11, 2026 · 📺 Danaher Corporation

    Advances in antibody conjugate science are changing the calculus for nucleic acid therapeutics. As the field moves from small molecule payloads toward oligonucleotides and RNA, the antibody is emerging as the determinant of whether a therapy reaches patients at all. John Cox, Dyne Therapeutics Moderated by Jose-Carlos Gutiérrez-Ramos, Danaher Watch more videos from Danaher's 2026 Summit:    • Danaher Summit 2026: The Next Era of Biopr...   ---- Stay connected with Danaher: Learn more about our work and impact: https://www.danaher.com Follow us on LinkedIn:   / danaher   Watch more stori…

    Watch on YouTube ↗

  • PPMD 2024 Annual Conference: Day 2 - Research Row: Strategies to Restore Dystrophin

    July 24, 2024 · 📺 Parent Project Muscular Dystrophy

    Research Row: Strategies to Restore Dystrophin Annemieke Aartsma-Rus, PhD, University of Leiden (Moderator) Avidity Biosciences - AOC 1044: Henry Nchienzia, PhD, Avidity Biosciences Biomarin - BMN 351: Peter Velzquez, PhD, BioMarin Pharmaceutical Inc. Dyne Therapeutics - DYNE-251: John Cox, MBA, Dyne Therapeutics Entrada Therapeutics - ENTR-601-44: Mahasweta Girgenrath, PhD, Entrada Therapeutics NS Pharma - NS-089 / NS-050: Robert Crozier, PhD, NS Pharma Pepgen - PGN-EDO51: Bassem Morcos, MD, Pepgen PTC Therapeutics - Ataluren: Jonathan Blaize, PhD, PTC Therapeutics Sarepta Therapeutics -…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →